Phase II trial of elinogrel in patients with stable coronary artery disease and high platelet reactivity who did not respond to clopidogrel.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 20 Nov 2008

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Elinogrel (Primary) ; Aspirin; Clopidogrel
Indications Coronary artery disease; Embolism and thrombosis
Focus Pharmacodynamics
Sponsors Portola Pharmaceuticals

Most Recent Events

11 Nov 2008 Results presented at the American Heart Association's Annual Scientific Sessions 2008.
11 Nov 2008 New trial record.

Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

IP authentication when working within your organization’s network.
Login with username/password or try access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days.
Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Contact your organization’s admin about adding this content to your AdisInsight subscription
Buy a PDF version of the profile.
Request a free trial

Welcome to AdisInsight